True regarding Denosumab

Denosumab, an antibody that blocks the RANK ligand (RANKL) and dramatically reduces osteoclast number and function, is approved for therapy of osteoporosis. It also appears to be an effective treatment to reverse hypercalcemia of malignancy. Jaw necrosis, atypical femoral fracture, skin infections , occasional severe hypocalcemia are the side effects. Ref Harrison 20th edi page no 2956